NASDAQ: EMPGEmpro Group Inc Stock
$17.36+0.00 (+0%)
Updated Nov 7, 2025
EMPG Price
$17.36
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$2.55
52 Week High
$18.14
P/E
157.82x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$5.48M
Earnings
$751.36k
Gross Margin
61.8%
Operating Margin
20.11%
Profit Margin
13.7%
Debt to Equity
4.1
Operating Cash Flow
$164k
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EMPG Overview
Malaysian beauty & personal care brand, evolving from eyebrow embroidery into cosmetics, skincare, and healthcare products, distributing across Southeast Asia and Europe
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EMPG's potential to beat the market
- EMPG doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Distribution
Industry Rating
A
EMPG
RankedUnranked of 6
RankedUnranked of 6
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $205.37 | A | |
| $71.43 | B | |
| $842.09 | B |
Be the first to know about important EMPG news, forecast changes, insider trades & much more!
EMPG News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EMPG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EMPG was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EMPG is poor value based on its earnings relative to its share price (157.82x), compared to the US market average (44.96x)
P/E vs Market Valuation
EMPG is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more EMPG due diligence checks available for Premium users.
Valuation
EMPG fair value
Fair Value of EMPG stock based on Discounted Cash Flow (DCF)
Price
$17.36
Fair Value
$0.17
Overvalued by
10,169.30%
EMPG was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EMPG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
157.82x
Industry
30.11x
Market
44.96x
EMPG is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EMPG is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
EMPG's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
EMPG's Earnings (EBIT) of $1.10M... subscribe to Premium to read more.
Interest Coverage Financials
EMPG's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.8M
Liabilities
$3.0M
Debt to equity
4.1
EMPG's short-term assets ($2.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EMPG's short-term assets ($2.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EMPG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
EMPG's operating cash flow ($164.45k)... subscribe to Premium to read more.
Debt Coverage Financials
EMPG vs Medical Distribution Stocks
Empro Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.